ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 24403232

PD-1 as a potential target in cancer therapy.

McDermott DF and 1 other. Cancer Med, 2013. Cited by 331 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. PD-1 as a potential target in cancer therapy. Papers, record 24403232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24403232

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
PD-1 as a potential target in cancer therapy.
PubMed
Journal
Cancer Med
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Review
PubMed
Citations, by iCite
331
iCite
Relative citation ratio, by iCite
8.37
iCite
Revised in PubMed
2022-04-08
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1McDermott DFDavid F
2Atkins MBMichael B

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunotherapyMajor topic
Molecular Targeted TherapyMajor topic
NeoplasmsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
Humans
Immune Tolerance
Neoplasm Proteins
Nivolumab

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P50 CA101942NCI NIH HHSUnited StatesP50CA101942PubMed and NIH
P50 CA101942-01NCI NIH HHSUnited StatesP50CA101942PubMed and NIH

Source NIH RePORTER

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03605589Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaBackgroundClinicalTrials.gov
NCT04846452Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLCBackgroundClinicalTrials.gov
NCT04973306Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCCBackgroundClinicalTrials.gov
NCT05280626First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPResultsClinicalTrials.gov
NCT06584435A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal CancerResultsClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References57

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120,514,286Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review.Can Urol Assoc J2010https://conductscience.org/library/papers/20514286PubMed
217,938,288Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.Circulation2007https://conductscience.org/library/papers/17938288PubMed
316,606,670Tissue expression of PD-L1 mediates peripheral T cell tolerance.J Exp Med2006https://conductscience.org/library/papers/16606670PubMed
422,461,641Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.Sci Transl Med2012https://conductscience.org/library/papers/22461641PubMed
51,396,582Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J1992https://conductscience.org/library/papers/1396582PubMed
610,485,649Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity1999https://conductscience.org/library/papers/10485649PubMed
712,787,564Costimulation of T cells by OX40, 4-1BB, and CD27.Cytokine Growth Factor Rev2003https://conductscience.org/library/papers/12787564PubMed
818,223,165B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.Blood2008https://conductscience.org/library/papers/18223165PubMed
910,581,077B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat Med1999https://conductscience.org/library/papers/10581077PubMed
1020,818,862Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med2010https://conductscience.org/library/papers/20818862PubMed

1 to 10 of 57

See all 57 references

Cited by225

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 331 citations.

PMIDTitleJournalYearIn PapersSource
42,964,272The synergistic potential of combining PD-1/PD-L1 inhibitors with conventional therapies in esophageal squamous cell carcinoma.Front Pharmacol2026https://conductscience.org/library/papers/42964272PubMed
42,894,226Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer.J Cardiothorac Surg2026https://conductscience.org/library/papers/42894226PubMed
42,846,110Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinoma.Oncol Rev2026https://conductscience.org/library/papers/42846110PubMed
42,741,758How to manage radioiodine-refractory thyroid cancer in the era of precision medicine.Drugs Context2026https://conductscience.org/library/papers/42741758PubMed
42,699,700Newcastle Disease Virus - Induced Interferons Regulate PD-L1 and MICA Expression in Human Tumor and Normal Cells.Immunotargets Ther2026https://conductscience.org/library/papers/42699700PubMed
42,667,630Advanced Materials for Biologics Delivery to Brain Tumors.Adv Mater2026https://conductscience.org/library/papers/42667630PubMed
42,604,150Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses.Mol Ther Oncol2026https://conductscience.org/library/papers/42604150PubMed
42,192,928Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?Cancers (Basel)2026https://conductscience.org/library/papers/42192928PubMed
41,809,120Recurrent Glioblastoma and the Tumor Immune Landscape: Emerging Immunotherapeutic Strategies.Immunotargets Ther2026https://conductscience.org/library/papers/41809120PubMed
41,681,896ABCB5: A Key Regulator Linking Stem Cell Plasticity, Tumor Microenvironment, and Therapy Resistance in Cutaneous Melanoma.Cancers (Basel)2026https://conductscience.org/library/papers/41681896PubMed

1 to 10 of 225

See all 225 cited by

Genes20

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FOXP350,943PubTator's text mininghttps://conductscience.org/library/genes/50943NCBI Gene
HLA-C3,107PubTator's text mininghttps://conductscience.org/library/genes/3107NCBI Gene
IFNG3,458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene

1 to 10 of 20

See all 20 genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
RITUXIMABCHEMBL1201576Results1https://conductscience.org/library/drugs/CHEMBL1201576ChEMBL
TORIPALIMABCHEMBL4297843Results1https://conductscience.org/library/drugs/CHEMBL4297843ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24403232

GET https://conductscience.org/api/papers/v1/24403232/references?page=2

API referenceFor AI assistants